Revenue more than doubled in 2025 following the successful launch of three cornerstone products: Incrolix, Galzyn, and Kinduvi.

Management attributes the 83% year-over-year Q4 revenue growth to increased sales of Alkindi Sprinkle and the addition of revenue from Incralex, Galzan, and Candivy.

The adjusted EBITDA margin expanded to 29% from 18%, driven by disciplined cost management and a shift toward higher-margin rare disease assets.

The Hemangiol acquisition follows a value-creation strategy of acquiring under-optimized assets to apply Eton's specialized rare disease commercial infrastructure.

Galzin performance exceeded internal expectations, reaching 300 active patients within one year by converting users from non-FDA-approved over-the-counter zinc supplements.

Strategic positioning focuses on 'Eton Cares,' a patient support program designed to eliminate financial barriers and improve physician prescribing confidence.

2026 guidance projects revenue exceeding $110 million with adjusted EBITDA margins of at least 30% as the portfolio scales.

Management set a new '200 by 27' goal, aiming for a $200 million revenue run rate by the end of 2027 through organic growth and at least one additional acquisition.

The Desmota launch strategy includes a 90-day pilot targeting adult endocrinologists to capture an addressable market three times larger than the pediatric population.

Long-term financial targets include reaching a 50% adjusted EBITDA margin by 2028 and $500 million in annual revenue by 2030.

The R&D pipeline is expected to be at its busiest in 2026, with five clinical studies planned to support label expansions and new NDAs.

The loss of the FDA small business exemption will result in $3.5 million in annual program fees, adding $2.8 million in incremental SG&A for 2026.

The Hemangiol integration includes hiring seven dedicated commercial employees from the seller to maintain momentum during the May 1 relaunch.

Gross margins may face temporary dilution in early 2026 due to lower-margin Incralex orders from international licensing partners.

The $14 million Hemangiol acquisition was funded entirely with cash on hand, avoiding shareholder dilution or new debt.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management plans to transition Hemangiol from a traditional wholesale model to a rare disease distribution model to reduce gross-to-net deductions.

Growth will be driven by implementing a zero-copay program to capture patients who previously opted for cheaper alternatives due to high costs.

Management expects the 'time to peak' for Desmota to be significantly faster than Alkindi due to a lack of existing compounding competitors.

Initial interest has been high, with institutions that previously declined sales visits proactively requesting meetings about the new liquid formulation.

The $200 million exit run rate for 2027 is based primarily on the existing portfolio and does not strictly require new M&A to be achieved.

Key drivers include the Hemangiol relaunch, Desmota growth, and the expected 2027 launch of the expanded Kinduvi label for children under five.

Eton submitted a study protocol to the FDA in February and expects feedback by the end of March 2026 to begin a 30-patient study.

The company intends to use interim data from the open-label study to approach the FDA for an earlier label update if results are compelling.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.